First patient enrolled in NG11-2 Phase Ib clinical trial Gallery First patient enrolled in NG11-2 Phase Ib clinical trial By Chloe Atkinson|2025-02-17T12:51:47+00:00May 8th, 2023|Clinical Development, News, NG11| Read More
VasoDynamics Receives UK MHRA-REC Approval On NG11-2 Phase Ib Clinical Trial Gallery VasoDynamics Receives UK MHRA-REC Approval On NG11-2 Phase Ib Clinical Trial By Chloe Atkinson|2025-02-17T12:45:13+00:00January 24th, 2023|Clinical Development, News, NG11| Read More
VasoDynamics files UK patent for Radiotherapy-Induced Oral Mucositis (RIOM) Clinical Trial Methodology Gallery VasoDynamics files UK patent for Radiotherapy-Induced Oral Mucositis (RIOM) Clinical Trial Methodology By Chloe Atkinson|2025-02-17T12:44:34+00:00December 22nd, 2022|Clinical Development, News| Read More
VasoDynamics submits UK Clinical Trial Application for NG11-2 Gallery VasoDynamics submits UK Clinical Trial Application for NG11-2 By Chloe Atkinson|2025-02-17T12:44:08+00:00October 21st, 2022|Clinical Development, News, NG11| Read More
VasoDynamics files global patent (PCT) for NG11-2 platform formulation and production Gallery VasoDynamics files global patent (PCT) for NG11-2 platform formulation and production By Chloe Atkinson|2025-02-17T12:42:10+00:00March 5th, 2022|Clinical Development, News, NG11| Read More
VasoDynamics completes MHRA advisory meeting for NG11-2 clinical development Gallery VasoDynamics completes MHRA advisory meeting for NG11-2 clinical development By Chloe Atkinson|2025-02-17T12:52:28+00:00September 21st, 2021|Clinical Development, News, NG11| Read More
